Company profile
Conexeu Sciences Inc.
NASDAQ: CNXU · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 27
v0.1 · 5/100 weight · pillars only
↑ market scale, filing timeliness · ↓ listing tenure, workforce scale
Methodology →Revenue TTM
—
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
—
Employees
4
as of 2026-08-01
Market cap
$173.9M
as of 2026-08-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
No filed financials — private or non-XBRL filer.
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Conexeu Sciences Inc.’s financial profile?
Conexeu Sciences Inc. has no structured financials on file — private or non-XBRL filer.
Peers · Healthcare
Atrium Therapeutics, Inc.——Acumen Pharmaceuticals, Inc.——Organigram Global Inc.——Tenaya Therapeutics, Inc.——Armata Pharmaceuticals, Inc.——Canton Strategic Holdings Inc——Neighbors
Washoe →Key facts
CEOMiles Harrison
SectorHealthcare
IndustryBiotechnology
HeadquartersReno, NV
ExchangeNASDAQ: CNXU
Employees4
IPO date2026-05-21
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.